ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Clearinghouse Insists On New Dichlorvos Test; CSWG Disagrees

March 24, 1978

Eight Scientists Receive $800,000 From Milken

January 12, 1990

In Brief: ACS Seeking Candidate for Holleb Replacement; NCI To Recruit AD For Biological Carcinogenesis

March 13, 1987

AACR Calls For Clear Statement; Says Report Was “Premature”

February 14, 1997

ASCO Annual Report Names Significant Clinical Research Advances Of Past Year

December 25, 2009

NCI Programs: Functional Imaging Centers Grant Program Approved By Advisors

December 11, 1998